Drug
NT 112 Autologous
NT 112 Autologous: highest development phase Phase 1, developed by AstraZeneca. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- AstraZeneca
Trials
| Drug | Phase | Indication |
|---|---|---|
| NT-112: Autologous, engineered T Cells targeting KRAS G12D NCT06218914 | Phase 1 | Non-small Cell Lung Cancer |
Latest
No recent events.
Follow NT 112 Autologous on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.